Androgen therapy in women: What we think we know

Drillich, Ann Dorothy; Davis, Susan Ruth

doi:10.1016/j.exger.2007.02.005

Cited by 16 publications

(12 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Women suffering from oestrogen deficiency should be recommended a number of measures to protect against osteoporosis, including increased physical exercise, eating a diet rich in calcium and vitamin D and avoiding risk factors such as smoking and high alcohol intake. It is contentious whether women with POF should also consider androgen supplementation; however, recent reviews have supported the addition of testosterone to HRT to improve sexual function and wellbeing (Drillich & Davis 2007).…”

Section: Treatmentmentioning

confidence: 99%

Premature ovarian failure

Shelling¹

2010

Reproduction

230

165

View full text Add to dashboard Cite

Premature ovarian failure (POF) is a common cause of infertility in women, and is characterised by amenorrhoea, hypo-oestrogenism and elevated gonadotrophin levels in women under the age of 40. Known causes include iatrogenic agents that cause permanent damage to the ovaries, such as chemotherapy, radiation therapy and surgery, autoimmune conditions, X-chromosome abnormalities and autosomal genetic conditions. However, few genes have been identified that can explain a substantial proportion of cases of POF. Most women with POF are deeply upset by the diagnosis, partly due to the unexpected menopausal symptoms, but also due to infertility. Therefore, early detection would provide better opportunity for early intervention, and furthermore, the identification of specific gene defects will help to direct potential targets for future treatment.

show abstract

Section: Treatmentmentioning

confidence: 99%

Premature ovarian failure

Shelling¹

2010

Reproduction

230

165

View full text Add to dashboard Cite

show abstract

“…[8][9][10][11][12] Dehydroepiandrosterone (DHEA) supplementation has been shown to improve ovarian response to stimulation. In women with reduced ovarian reserve, androgen supplementation seems to improve ovarian response to stimulation.…”

Section: Orthodox Medical Preventative Optionsmentioning

confidence: 99%

Clinical issues during ART

Szmelskyj

2015

Acupuncture for IVF and Assisted Reproduction

View full text Add to dashboard Cite

“…The indication is likely to be extended to naturally menopausal women [39]. In the United Kingdom, subcutaneous testosterone implants are approved for therapy, as well as in Australia, where 1% testosterone creams are also available [40]. In the United States, there are no FDA‐approved androgen treatments.…”

Section: Treatment Options In the United Statesmentioning

confidence: 99%

Testosterone Replacement Therapy in Naturally and Surgically Menopausal Women (CME)

Panzer

Guay

2009

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Introduction Testosterone replacement therapy in naturally and surgically menopausal women is a complex and currently highly debated topic. Opposing guidelines for the use of testosterone exist, which create a therapeutic dilemma for clinicians confronted by severely distressed women who experience a decrease in sexual desire after surgical or natural menopause. Aim In this review, we will address the current knowledge on androgen physiology, conditions associated with a low androgen state, and risks and benefits of androgen therapy. Methods An English-language Medline review was performed. Main Outcome Measure Review of available literature. Results A review of normal androgen physiology in women is summarized and a brief review of prior use of androgens over the last six decades is included. The data on the use of androgen replacement in pre- and postmenopausal women is evaluated, especially its relationship to sexual functioning. Special concerns about the effect of androgens on cardiovascular disease, breast, and endometrial tissue are discussed. The balance of evidence seems to show that androgens have more of a positive effect than a negative effect in women if used properly. Conclusions Testosterone replacement therapy for surgically and naturally menopausal women with low sexual desire can be accomplished physiologically and effectively after ruling out other medical conditions leading to low sexual desire and after proper information of the patient that testosterone therapy is not an FDA-approved medication in the United States. The majority of available data suggests that testosterone replacement in women can be used safely without increased risk of endometrial or breast cancer.

show abstract

Androgen therapy in women: What we think we know

Cited by 16 publications

References 28 publications

Premature ovarian failure

Premature ovarian failure

Clinical issues during ART

Testosterone Replacement Therapy in Naturally and Surgically Menopausal Women (CME)

Contact Info

Product

Resources

About